CT Coronary Angiography in Acute Chest Pain
Definition
CT coronary angiography (CTCA) in acute chest pain is the use of a noninvasive coronary CT angiogram, usually after myocardial infarction has been ruled out by high-sensitivity troponin, to detect coronary artery disease, guide preventive therapy and triage further investigation. The clinical question is not whether CTCA can image the coronary tree — it can, reliably, in most patients — but whether adding it to a troponin-based pathway changes the outcomes that matter: myocardial infarction, cardiac death and downstream care. (sources/TARGET-CTCA-NEJM-2026, rating: high)
Key Concepts
Rationale and Risk Stratification
- Acute chest pain accounts for 5–10% of emergency department visits; accelerated diagnostic pathways using high-sensitivity troponin can rule out MI and support safe discharge.
- Among patients in whom MI is ruled out, the maximum troponin concentration still stratifies risk: values above the low-risk threshold but below the sex-specific 99th percentile identify an intermediate-risk group with about twice the prevalence of coronary disease on CTCA and a tenfold higher one-year risk of MI or cardiac death than very low troponin. (sources/TARGET-CTCA-NEJM-2026, rating: high)
- Guidelines recommend considering CTCA or noninvasive stress imaging in this intermediate-risk group, but the recommendations were built on trials that measured length of stay and discharge, not hard outcomes.
The TARGET-CTCA Trial
| Element | Detail |
|---|---|
| Population | 3,170 adults with suspected ACS, MI ruled out, maximum high-sensitivity troponin >5 ng/L and below the sex-specific 99th percentile; median age 61; 30.2% women |
| Intervention | Outpatient CTCA-guided care plus standard care versus standard care alone |
| CTCA delivery | 92.1% underwent CTCA, median 22 days after randomization |
| CT findings | Normal 31.8%, nonobstructive disease 42.5%, obstructive disease 22.6% |
| Primary outcome | Myocardial infarction or cardiac death at a median 3.0 years: 7.1% versus 7.3%; adjusted HR 0.95 (95% CI 0.73–1.23); P=0.71 |
| Secondary outcomes | MI 5.9% versus 6.3%; cardiac death 1.4% versus 1.7%; all-cause death 4.6% versus 6.1% (not multiplicity-adjusted) |
| Care change | Antiplatelet use 42.4% versus 32.8% and statin use 63.4% versus 48.5% at 90 days |
| Safety | CTCA-related adverse events 0.4%, all mild |
(sources/TARGET-CTCA-NEJM-2026, rating: high)
Detection versus Outcome Benefit
- CTCA identified obstructive disease in 22.6% and nonobstructive disease in 42.5%, and it increased antiplatelet and statin prescribing. None of that translated into fewer MIs or cardiac deaths.
- The null result is not explained by a failed intervention: 92.1% of the intervention arm underwent CTCA, and only 2.2% of the standard-care arm had nontrial CTCA within 90 days.
- Possible explanations include a population already receiving contemporary preventive therapy, a lower-than-expected event rate, and the possibility that CTCA changes management without changing the events that matter. (sources/TARGET-CTCA-NEJM-2026)
Subgroups and the Risk-Score Paradox
- The effect was consistent across sex, age, known coronary disease, baseline preventive therapy, troponin assay and troponin concentration.
- By HEART score, CTCA appeared to favour low-risk participants (HR 0.58, 95% CI 0.35–0.98) and not intermediate- or high-risk participants (HR 1.11, 0.81–1.50). The trial was not designed or powered for this interaction, and it was not adjusted for multiplicity, so the finding is hypothesis-generating.
- The apparent paradox — benefit in the group with lower risk-score burden — may reflect the fact that high-risk patients were already receiving more intensive care, leaving less room for CTCA to change management.
Guideline Context
- The 2021 AHA/ACC chest pain guideline gives CTCA a Class 1A recommendation in intermediate-risk acute chest pain to rule out obstructive coronary disease; the 2023 ESC ACS guideline gives CTCA or noninvasive stress imaging a IIa/A recommendation in patients without elevated troponin. (sources/TARGET-CTCA-NEJM-2026, rating: high)
- TARGET-CTCA does not invalidate those recommendations for diagnosis and triage, but it removes the assumption that routine CTCA in this pathway reduces hard cardiac events.
- The ongoing FAST-CCTA trial is testing CTCA in emergency-department patients with HEART score >3 and may clarify whether a higher-risk score-defined population benefits.
Relationship to Other CTCA Strategies
- In stable chest pain, CTCA has been shown to reduce downstream events in some trials, but the populations and the background care differ from the acute post-rule-out setting.
- When CTCA is used before PCI, it can shift procedural planning upstream and shorten the invasive procedure; that is a different use of the same test, addressed on concepts/CCTA-Guided-PCI.
- The test's value in acute chest pain therefore depends on the question being asked: diagnosis and triage versus hard-event reduction versus procedural planning.
Contradictions / Open Questions
- Guideline recommendation versus outcome evidence. The Class 1A/IIa recommendations for CTCA in intermediate-risk acute chest pain predate TARGET-CTCA and rest on trials of length of stay and discharge. The largest outcome trial now shows no reduction in MI or cardiac death, so the recommendation may need to be re-framed around diagnosis rather than prognosis. (sources/TARGET-CTCA-NEJM-2026, rating: high)
- Why did a test that found disease and changed prescribing not change events? The population was already on substantial preventive therapy, the event rate was lower than projected, and the absolute difference in statin use was modest. Whether a higher-risk population, a faster time to CTCA or a more intensive post-CTCA care pathway would produce a benefit is unknown.
- The HEART-score subgroup points the opposite way from the trial's overall result. CTCA appeared to help low-risk patients and not high-risk patients, which is the reverse of the intuitive expectation. The interaction is underpowered and may be chance; it cannot be used to select patients.
- The confidence interval still permits a clinically important benefit or harm. The result is compatible with a 27% relative reduction to a 23% relative increase; the trial is a well-powered null, not a proof of no effect.
- Women are under-represented and may be systematically under-classified. The sex-specific 99th percentile is lower in women, so fewer women meet the intermediate-risk troponin definition; the trial's 30.2% female proportion limits sex-specific inference.
- The trial says nothing about CTCA performed at presentation. CTCA was done at a median of 22 days after randomization in the outpatient setting. Whether immediate inpatient CTCA changes outcomes is a different question.
- Cost-effectiveness and downstream testing are unresolved. CTCA increased cardiology visits and invasive angiography without reducing events; whether the diagnostic information is worth the resource use depends on values and health-system costs that the trial did not fully capture.
Connections
- Part of concepts/ACS-Management — the acute coronary syndrome pathway
- concepts/ASCVD-Risk-Assessment — troponin-based risk stratification and preventive therapy
- concepts/CCTA-Guided-PCI — the procedural-planning use of coronary CT angiography
- concepts/Dyslipidemia-Management — statin initiation after coronary disease detection
- entities/Acute-Coronary-Syndrome — the presenting syndrome
- entities/Chronic-Coronary-Disease — the downstream framework for nonobstructive and obstructive disease